PIN-A1 / Pin Therap - LARVOL DELTA

A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells. (PubMed, Cancer Res) - "In conclusion, PinA1 degrades CK1⍺, activates the p53 pathway, and induces cell-cycle arrest and apoptosis in TP53 wild-type AML cells. The robust anti-leukemic efficacy of PinA1, both as monotherapy and further in combination with targeted agents, along with its minimal toxicity to normal hematopoietic cells, underscores its potential for future clinical applications."

IO biomarker • Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Targeted Protein Degradation • BCL2 • CD34 • FLT3

Pintherapeutics Selects KDDF Project for TPD-Based Solid Tumor Treatment [Google translation] (Hankyung) - "Pintherapeutics announced on the 4th that the non-clinical study of its ‘CK1α selective degrader’ was selected as a project of the ‘Excellent new drug development support project for promoting global expansion and partnering’ by the Korea Drug Development Foundation (KDDF)....Pin Therapeutics aims to submit an IND (Investigational New Drug) for the CK1α selective degrader to the US Food and Drug Administration (FDA) within the next year and enter clinical trials."

Financing • IND • Oncology • Solid Tumor

Discovery of potent and selective CK1α molecular degrader with a favorable safety profile for acute myeloid leukemia and solid tumors (AACR 2023) - "Also, we found that the combination treatment of PIN-A1 with agent X had a substantial effect on several solid tumors driven by enhancing the stability and activity of p53. In summary, these results suggest that a CK1α MGD with its favorable safety profile has a potential to become an effective treatment option for advanced AML and solid tumors."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • CRBN